Travere Therapeutics, Inc. (TVTX)
$
34.29
-0.71 (-2.07%)
Key metrics
Financial statements
Free cash flow per share
-0.7682
Market cap
3.1 Billion
Price to sales ratio
7.1847
Debt to equity
4.4825
Current ratio
2.7475
Income quality
0.6620
Average inventory
4.8 Million
ROE
-1.7868
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The weighted average number of shares outstanding is 78,889,000.00 highlighting the company's shareholder base. The net total of other income and expenses is $3,317,000.00 reflecting non-core financial activities. The income before tax ratio is -1.37 reflecting the pre-tax margin. Meanwhile, the EBITDA ratio is -1.14 highlighting the company's operational efficiency. Additionally, the weighted average number of diluted shares outstanding is 78,889,000.00 reflecting potential dilution effects as it navigates its market position. Travere Therapeutics, Inc. operates within the biopharmaceutical landscape, focusing on the identification, development, and commercialization of therapies for rare diseases. Its marketed products include Chenodal, a synthetic oral formulation for treating radiolucent stones in gallbladders, Cholbam, a cholic acid capsule for various bile acid synthesis disorders, and Thiola and Thiola EC for treating homozygous cystinuria. Additionally, the company's product candidates include Sparsentan and TVT-058, targeting serious nephrological conditions through clinical trials. Through its cooperative research and development agreements, Travere seeks to advance treatment options for conditions such as NGLY1 deficiency and Alagille syndrome. The stock is affordable at $24.85 suitable for budget-conscious investors. The stock has a high average trading volume of 2,127,388.00 indicating strong liquidity in the marketplace. With a market capitalization of $3,067,779,847.00 the company is classified as a small-cap player within the industry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the healthcare sector, driving innovation and growth while maintaining a commitment to improving the lives of patients with rare diseases. Through its structured approach and dedicated research, Travere Therapeutics continues to make strides in advancing therapeutic solutions, positioning itself as a vital entity in the quest for novel treatments for challenging health conditions.
Is Travere Therapeutics, Inc. (TVTX) a good investment?
Investing in Travere Therapeutics, Inc. (TVTX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Travere Therapeutics, Inc. (TVTX)'s stock forecast?
Analysts predict Travere Therapeutics, Inc. stock to fluctuate between $12.91 (low) and $37.50 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Travere Therapeutics, Inc.'s market capitalization?
As of 2025-12-08, Travere Therapeutics, Inc.'s market cap is $3,067,779,847, based on 89,465,729 outstanding shares.
How does Travere Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Travere Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Travere Therapeutics, Inc. (TVTX) stock?
To buy Travere Therapeutics, Inc. (TVTX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TVTX. Place an order (Market, Limit, etc.).
What is the best time to invest in Travere Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Travere Therapeutics, Inc. stock ever split?
Travere Therapeutics, Inc.'s last stock split was 1:9 on 2012-11-02.
How did Travere Therapeutics, Inc. perform in the last earnings report?
Revenue: $233,175,000 | EPS: -$4.08 | Growth: 172%.
Where can I find Travere Therapeutics, Inc.'s investor relations reports?
Visit https://www.travere.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Travere Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Travere Therapeutics, Inc. stock?
All-time high: $37.50 (2025-11-28) | All-time low: $5.12 (2024-04-25).
What are the key trends affecting Travere Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) reached a new 52-week high on Friday. The company traded as high as $37.50 and last traded at $36.0350, with a volume of 97887 shares. The stock had previously closed at $36.26. Wall Street Analysts Forecast Growth A number of equities analysts have issued reports on
fool.com
New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valued at $160.7 million.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual Healthcare Innovation Conference Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 TD Cowen Immunology & Inflammation Summit Presenting on Thursday, November 13, 2025, at 4:00 p.m. ET Jefferies Global Healthcare Conference Pr.
seekingalpha.com
Travere Therapeutics, Inc. ( TVTX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Nivi Nehra - Vice President of Corporate Communications & Investor Relations Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Chief Research Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Laura Chico - Wedbush Securities Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call.
zacks.com
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday, October 30, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentation.
zacks.com
Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
seekingalpha.com
Initiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S. net product revenues growing by 165% year-over-year to $71.9 million. A key catalyst is the January 13, 2026 PDUFA date for Filspari's sNDA in FSGS, potentially making it the first approved treatment for this rare kidney disorder.
zacks.com
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
zacks.com
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
See all news
